A Multicenter, Double-blind, Randomized, Parallel-group Study to Compare the Effect of 24 Weeks Treatment With Vildagliptin 50mg qd to Placebo as add-on Therapy to Glimepiride in Patients With Type 2 Diabetes Inadequately Controlled With Sulfonylurea Monotherapy.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 31 May 2014

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vildagliptin (Primary) ; Glimepiride
Indications Type 2 diabetes mellitus
Focus Therapeutic Use
Sponsors Novartis

Most Recent Events

01 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
05 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
03 May 2012 Planned number of patients changed from 272 to 128 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight